文献速递癫痫神经重症与神经感染

抗癫痫药物三联疗法在难治性癫痫胶质瘤患者中的有效性:一项观察性队列研究

Effectiveness of Antiseizure Medication Triple Therapy in Patients With Glioma With Refractory Epilepsy: An Observational Cohort Study.
PubMed 文献 · Neurology · 2023-02-08

这项多中心回顾性观察性队列研究纳入1435例胶质瘤患者,其中90例因二线抗癫痫药物失败后接受三联治疗,评估左乙拉西坦联合丙戊酸和氯巴占(LEV+VPA+CLB)与其他三联方案的有效性。结果显示LEV+VPA+CLB与其他三联方案在治疗失败、癫痫控制及不良反应方面均无统计学显著差异。

要点

  • 胶质瘤合并癫痫患者中约10%因难治性癫痫需要抗癫痫药物三联治疗。
  • LEV+VPA+CLB组与其他三联方案组12个月任何原因治疗失败累积发生率无显著差异。
  • LEV+VPA+CLB组与其他三联方案组在癫痫失控、不良反应及癫痫复发方面均无显著差异。

核心结论

  • LEV+VPA+CLB与其他抗癫痫药物三联方案相比可能具有等效的有效性。
  • 本研究提供III级证据表明LEV+VPA+CLB与其他三联方案在有效性和耐受性方面相似。

研究设计与样本

  • 多中心回顾性观察性队列研究。
  • 原始队列1435例患者中,90例因癫痫失控在二线抗癫痫药物治疗失败后接受三联治疗。
  • LEV+VPA+CLB组43例(48%),其他三联方案组47例(52%)。
  • 随访最长时间为36个月。

主要发现

  • 任何原因治疗失败12个月累积发生率:LEV+VPA+CLB组47%(95%CI 31%-62%)vs 其他三联方案组42%(95%CI 27%-56%),p=0.892。
  • 癫痫失控导致治疗失败12个月累积发生率:LEV+VPA+CLB组12%(95%CI 4%-25%)vs 其他三联方案组18%(95%CI 8%-30%),p=0.445。
  • 不良反应导致治疗失败12个月累积发生率:LEV+VPA+CLB组22%(95%CI 11%-36%)vs 其他三联方案组15%(95%CI 7%-27%),p=0.446。
  • 癫痫复发1个月累积发生率:LEV+VPA+CLB组65%(95%CI 48%-78%)vs 其他三联方案组63%(95%CI 47%-75%),p=0.911。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Approximately 10% of patients with glioma with epilepsy need antiseizure medication (ASM) triple therapy due to refractory epilepsy. The aim of this study was to evaluate whether levetiracetam combined with valproic acid and clobazam (LEV + VPA + CLB), a frequently prescribed triple therapy, has favorable effectiveness compared with other triple therapy combinations in patients with glioma. METHODS: This was a multicenter retrospective observational cohort study. The primary outcome was the cumulative incidence of time to treatment failure for any reason, from the start of ASM triple therapy treatment. The secondary outcomes included cumulative incidences of the following: (1) time to treatment failure due to uncontrolled seizures; (2) time to treatment failure due to adverse effects; and (3) time to recurrent seizures. Patients were followed up for a maximum duration of 36 months. RESULTS: Of 1,435 patients in the original cohort, 90 patients received ASM triple therapy after second-line ASM treatment failure due to uncontrolled seizures. LEV + VPA + CLB was prescribed to 48% (43/90) and other ASM triple therapy to 52% (47/90) of patients. The cumulative incidence of treatment failure for any reason of LEV + VPA + CLB did not statistically significantly differ from that of other ASM triple therapy combinations (12 months: 47% [95% CI 31%-62%] vs 42% [95% CI 27%-56%], p = 0.892). No statistically significant differences for treatment failure due to uncontrolled seizures (12 months: 12% [95% CI 4%-25%] vs 18% [95% CI 8%-30%], p = 0.445), adverse effects (12 months: 22% [95% CI 11%-36%] vs 15% [95% CI 7%-27%], p = 0.446), or recurrent seizures (1 month: 65% [95% CI 48%-78%] vs 63% [95% CI 47%-75%], p = 0.911) were found. DISCUSSION: LEV + VPA + CLB might show equivalent effectiveness compared with other ASM triple therapy combinations in patients with glioma. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with glioma with refractory epilepsy on triple therapy ASMs, LEV + VPA + CLB demonstrated similar effectiveness and tolerability compared with other ASM triple therapy combinations.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. van der Meer PB, Dirven L, Fiocco M, et al. Effectiveness of Antiseizure Medication Triple Therapy in Patients With Glioma With Refractory Epilepsy: An Observational Cohort Study. Neurology. 2023. PMID: 36754633. doi:10.1212/WNL.0000000000206852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。